American Regent competitors

C-Level Executive with demonstrated leadership skills and proven business results in Pharmaceuticals (Branded and Generics), Sales, Marketing, Operations, Business Development, R&D/Regulatory.I'm a creative problem-solver, with a track record of outstanding results through professional and interpersonal skills including strategic vision, team development, people management, prioritization, motivation, decisiveness and grit.

Mr. Ward has been a member of our Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer. Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC, and may provide limited advisory and consulting services to Sightline Partners in this capacity.

John has over 20 years of healthcare experience with 10 years directly in the cancer field. He is a board member or trusted advisor on active investments in Cancer, Dermatology, Diabetes, Anatomical Pathology, Generic Pharmaceuticals, Nuclear Pharmaceuticals, Health Payments and Health Information Technology through Bioveda China Fund, Amorperum Health and with a small number of top tier Private Equity Healthcare Firms. He is very active in board roles with a variety of healthcare companies in Israel, China, India and the US. Some of his past boards include Prodigy Health, which sold to Aetna (NYSE:AET) , and CITIC Pharmaceuticals, which sold to Shanghai Pharmaceuticals (SH:601607). Previously, John was the CEO of Oncology Therapeutics Network, which sold to McKesson, President of Oncology Services at Bristol Myers Squibb, and a Vice President at McKesson. He was a co- founder of Cancer Centers of Excellence and an early investor in Oncology Molecular Imaging. John studied economics and physics at University of California at Davis and has a Bachelor of Science from University of the State of New York. John served for 12 years in the United States Air Force and Air National Guard. He is currently a member of YPO and is active with the Wounded Warrior Project.

Craig Landau is a President/CEO at Purdue Biopharma LP and President/CEO at PURDUE PHARMA and is based in Stamford, Connecticut. He has worked as Major at United States Army, Associate Medical Director at Knoll Pharmaceutical Co, and Executive Medical Director at PURDUE PHARMA. Craig attended WINTHROP-UNIVERSITY HOSPITAL between 1991 and 1992, Icahn School of Medicine at Mount Sinai between 1987 and 1991, and Yale University-School of Medicine between 1992 and 1995.

David Seltzer is a Chairman/Pres/CEO/Treasurer at HI TECH PHARMACAL CO INC, Board Member at NovelStem International Corp, and Owner at Leading Pharma. He has experience at Bergen Brunswig Corp and AMERISOURCEBERGEN CORP and has worked as Exec VP:Admin/Treasurer/Secy at HI TECH PHARMACAL CO INC, Treasurer/Secretary at HI TECH PHARMACAL CO INC, and VP:Admin/COO/Treasurer/Secy at HI TECH PHARMACAL CO INC. David attended Queens University of Charlotte.